Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | PPARD | Q03181 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 4/20 | 0.55 |
| ▸ | HTR6 | P50406 | 14/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487054 | 0.87 | PPARG (0.65) | PPARGPPARDPPARAHTR6KDM4E | |
| SCHEMBL13865486 | 0.81 | PPARG (0.48) | PPARGPPARDPPARAHTR6ALDH1A1 | |
| SCHEMBL4476844 | 0.78 | PPARG (0.53) | PPARGPPARDPPARAHTR6KDM4E | |
| SCHEMBL5326101 | 0.78 | HTR6 (0.68) | PPARGPPARDPPARAHTR6 | |
| SCHEMBL5329599 | 0.78 | HTR6 (0.53) | PPARGPPARDPPARAHTR6 | |
| SCHEMBL4619062 | 0.76 | PPARG (0.55) | PPARGPPARDPPARAHTR6 | |
| SCHEMBL4619058 | 0.76 | PPARG (0.55) | PPARGPPARDPPARAHTR6 | |
| SCHEMBL5327662 | 0.76 | HTR6 (0.70) | PPARGPPARDPPARAHTR6 | |
| SCHEMBL4620361 | 0.73 | PPARG (0.52) | PPARGPPARDPPARAHTR6ALDH1A1 | |
| SCHEMBL950479 | 0.73 | PPARG (0.73) | PPARGPPARDPPARAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531568-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531568-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531568-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1819673-A2 | INDOLE DERIVATIVES FOR USE AS PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006060456-A2 | INDOLE DERIVATIVES FOR USE AS PPAR PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116416-A1 | PPAR active compounds | PLEXXIKON, INC | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116416-A1 | PPAR active compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.